Last reviewed · How we verify
MSI-195
At a glance
| Generic name | MSI-195 |
|---|---|
| Sponsor | MSI Methylation Sciences, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of the Safety and Pharmacokinetics of MSI-195 to a Commercial S-Adenosylmethionine (PHASE1)
- Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MSI-195 CI brief — competitive landscape report
- MSI-195 updates RSS · CI watch RSS
- MSI Methylation Sciences, Inc. portfolio CI